Ceftazidime-avibactam in ceftazidime-resistant infections

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam

Ceftazidime in neonatal infections.

Ninety one neonates received 108 courses of intravenous ceftazidime (25 mg/kg, 12 hourly) over a study period of 15 months. Fourteen had clinically and bacteriologically proved infections. Only one of these had resistant organisms. Four (two with group B beta haemolytic streptococcal infections, one with Escherichia coli meningitis, and one with Staphylococcal aureus septicaemia) failed to resp...

EVALUATION OF CEFTAZIDIME ANTIMICROBIAL ACTIVITY IN INFECTIONS CAUSED BY BURNS

In vitro evaluation of ceftazidime antimicrobial activity in infections caused by burn and its comparison to the other antibiotics is presented. In vitro tests for susceptibility to ceftazidime and other antibiotics were carried out on 744 bacterial strains collected from burn infections. The results have shown that generally ceftazidime was more active against Pseudomollas aeruginosa an...

Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation.

Enterobacteriaceae are an important cause of infections, and the infection recurred weeks after finishing the antibiotic cycle, which led to another hospitalisation. For this reason, we decided to initiate treatment with the recent antibiespecially in immunocompromised patients. The recent appearance of carbapenemase-producing enterobacteriaceae otic ceftazidime–avibactam (C–A) for 2 weeks at a...

Ceftazidime-Resistant Salmonella enterica, Morocco

To the Editor: Many thanks for your interesting and informative special section on infectious diseases in the Amazon Region (1). Your readers should also be interested in a little known, but extremely successful, sustainable health program that had its start in the Amazon. In 1942, the governments of Brazil and the United States agreed to establish a special service for public health (called th...